Wednesday, July 8, 2026

biotech · Type 1 Diabetes · Coronavirus · SABS

SAB Biotherapeutics

SAB Biotherapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Gaithersburg, USA HQ
2016 Founded
39 Employees
Public company Type
SABS · NYSE Ticker
Company details
Status
Public
HQ
Gaithersburg, USA
Founded
2016
Employees
39
Programs
8
Drugs
10
Patents
1
Intelligence · Clinical Programs

SAB Biotherapeutics projects

4 ClinicalTrials.gov programs sponsored by SAB Biotherapeutics.

SAB Biotherapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. SAB-176

    SAB Biotherapeutics

    Influenza Type A

    phase 1 mab completed

    1 trial
  2. SAB-185

    SAB Biotherapeutics

    COVID-19

    phase 1 mab active

    2 trials
  3. SAB-301

    SAB Biotherapeutics

    Middle East Respiratory Syndrome Coronavirus

    phase 1 mab completed

    1 trial
  4. Single Ascending Dose of SAB-176

    SAB Biotherapeutics

    PHA1A

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does SAB Biotherapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.